relugolix (Rx)

Brand and Other Names:Orgovyx
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet

  • 120mg

Prostate Cancer

Indicated for advanced prostate cancer

Day 1 loading dose: 360 mg PO

Maintenance dose: 120 mg PO qDay

Dosage Modifications

Renal impairment

  • Mild-to-severe (CrCl 15-89 mL/min): No dosage adjustment required
  • End-stage renal disease with or without hemodialysis: Not studied

Hepatic impairment

  • Mild-to-moderate (Child-Pugh A or B): No dosage adjustment required
  • Severe (Child-Pugh C): Not studied

P-gp inhibitors

  • Avoid coadministration; if unable to avoid, take relugolix first and separate dosing by at least 6 hr
  • May briefly interrupt relugolix treatment for up to 2 weeks if a short course of treatment with a P-gp inhibitor is required
  • If treatment interrupted for >7 days, resume relugolix with 360 mg loading dose on the first day, followed by 120 mg/day

Combined P-gp and strong CYP3A inducers

  • Avoid coadministration; if unable to avoid, increase relugolix dose to 240 mg qDay; resume 120 mg qDay after discontinuing the strong P-gp/CYP3A inducer

Dosing Considerations

Correct electrolyte abnormalities

Consider periodic ECG and electrolyte monitoring

Males with female partners of reproductive potential should use effective contraception

Not indicated

Next:

Interactions

Interaction Checker

and relugolix

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (0)

                  Minor (0)

                    Previous
                    Next:

                    Adverse Effects

                    >10%

                    All grades

                    • Hot flush (54%)
                    • Glucose increased (44%)
                    • Triglycerides increased (35%)
                    • Musculoskeletal pain (30%)
                    • Hemoglobin decreased (28%)
                    • ALT increased (27%)
                    • Fatigue (26%)
                    • AST increased (18%)
                    • Diarrhea (12%)
                    • Constipation (12%)

                    1-10%

                    All grades

                    • Increased weight (<10%)
                    • Insomnia (<10%)
                    • Gynecomastia (<10%)
                    • Hyperhidrosis (<10%)
                    • Depression (<10%)
                    • Decreased libido (<10%)

                    Grade 3-4

                    • Glucose increased (2.9%)
                    • Triglycerides increased (2%)
                    • Musculoskeletal pain (1.1%)

                    <1%

                    Grade 3-4

                    • Hot flush
                    • Fatigue
                    • Diarrhea
                    • ALT increased
                    • Hemoglobin increased
                    Previous
                    Next:

                    Warnings

                    Contraindications

                    None

                    Cautions

                    Based animal studies and mechanism of action, fetal harm may occur

                    Therapy suppresses pituitary gonadal system; results of diagnostic tests conducted during and after treatment may be affected; monitor therapeutic effect of relugolix by measuring serum concentrations of prostate specific antigen (PSA) periodically; if PSA increases, measure serum testosterone concentrations

                    QT/QTc interval prolongation

                    • Androgen deprivation therapy may prolong QT/QTc interval
                    • Consider benefits and risks in patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities, and those taking drugs known to prolong QT interval
                    • Correct electrolyte abnormalities
                    • Consider periodic ECG and electrolyte monitoring

                    Drug interaction overview

                    • CYP enzymes: Substrate of CYP3A (primarily) and CYP2C8 (minor)
                    • Transporter systems: Substrate of P-gp; inhibitor of BCRP and P-gp
                    • P-gp inhibitors
                      • Avoid coadministration
                      • Coadministration increases relugolix AUC and peak plasma concentration; if unable to avoid, adjust time between dosing relugolix and the P-gp inhibitor
                    • Combined P-gp and strong CYP3A inducers
                      • Avoid coadministration
                      • Coadministration decreases relugolix AUC and peak plasma concentration; if unable to avoid, adjust relugolix dose
                    Previous
                    Next:

                    Pregnancy & Lactation

                    Pregnancy

                    Based on findings in animals and mechanism of action, can cause fetal harm and loss of pregnancy when administered to pregnant females

                    Human data are unavailable

                    Animal studies

                    • Administration to pregnant rabbits during organogenesis caused embryofetal lethality at maternal exposures that were 0.3 times the human exposure at the recommended dose of 120 mg daily based on AUC

                    Contraception

                    • Males with female partners of reproductive potential: Use effective contraception during treatment and for 2 weeks after last dose

                    Infertility

                    • Based on findings in animals and mechanism of action, may impair fertility in males of reproductive potential

                    Lactation

                    Data are unavailable on presence in human milk, effects on breastfed children, or effects on milk production

                    Relugolix and/or its metabolites were present in milk of lactating rats at concentrations up to 10-fold higher than in plasma at 2 hr post dose

                    Pregnancy Categories

                    A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                    B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                    C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                    D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                    X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                    NA: Information not available.

                    Previous
                    Next:

                    Pharmacology

                    Mechanism of Action

                    Gonadotropin-releasing hormone (GnRH) receptor antagonist; binds to and blocks GnRH receptors in the anterior pituitary gland

                    Blocking GnRH receptors decreases the release of gonadotropins (ie, luteinizing hormone, follicle stimulating hormone), thereby decreasing the downstream production of testosterone by the testes in men

                    Absorption

                    Absolute bioavailability: ~12%

                    Peak plasma time: 2.25 hr

                    Peak plasma concentration

                    • 360 mg: 215 ng/mL
                    • 120 mg: 70 ng/mL

                    AUC

                    • 360 mg: 985 nghr/mL
                    • 120 mg: 407 nghr/mL

                    Distribution

                    Protein bound: 68-71%; albumin (primarily), alpha1-acid glycoprotein (less extent)

                    Blood/plasma ratio: 0.78

                    Metabolism

                    Metabolized primarily by CYP3A and to lesser extent by CYP2C8 in vitro

                    Elimination

                    Half-life: 25 hr; terminal half-life 60.8 hr

                    Total clearance: 29.4 L/hr

                    Renal clearance: 8 L/hr

                    Excretion: Feces (81%; 4.2 unchanged); urine (4.1%; 2.2 unchanged)

                    Previous
                    Next:

                    Administration

                    Oral Administration

                    Take at approximately the same time each day

                    May take with or without food

                    Swallow tablets whole; do not crush or chew

                    Patients treated with GnRH receptor agonists and antagonists for prostate cancer is usually continued upon development of nonmetastatic or metastatic castration-resistant prostate cancer

                    Missed dose

                    • Take missed dose as soon as remembered
                    • Dose missed by >12 hours: Do not take missed dose; resume with next scheduled dose
                    • Treatment interrupted for >7 days: Restart with 360-mg loading dose on first day, and then continue 120 mg qDay

                    Storage

                    Store at room temperature; not to exceed 30ºC (86ºF)

                    Dispense in original container only

                    For bottles, keep container tightly closed after first opening

                    Previous
                    Next:

                    Images

                    No images available for this drug.
                    Previous
                    Next:

                    Patient Handout

                    A Patient Handout is not currently available for this monograph.
                    Previous
                    Next:

                    Formulary

                    FormularyPatient Discounts

                    Adding plans allows you to compare formulary status to other drugs in the same class.

                    To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                    Adding plans allows you to:

                    • View the formulary and any restrictions for each plan.
                    • Manage and view all your plans together – even plans in different states.
                    • Compare formulary status to other drugs in the same class.
                    • Access your plan list on any device – mobile or desktop.

                    The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                    Tier Description
                    1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                    2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                    3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                    4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                    NC NOT COVERED – Drugs that are not covered by the plan.
                    Code Definition
                    PA Prior Authorization
                    Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                    QL Quantity Limits
                    Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                    ST Step Therapy
                    Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                    OR Other Restrictions
                    Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                    Additional Offers
                    Email to Patient

                    From:

                    To:

                    The recipient will receive more details and instructions to access this offer.

                    By clicking send, you acknowledge that you have permission to email the recipient with this information.

                    Email Forms to Patient

                    From:

                    To:

                    The recipient will receive more details and instructions to access this offer.

                    By clicking send, you acknowledge that you have permission to email the recipient with this information.

                    Previous
                    Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.